Publications 2023
403.
Ahluwalia TS, Rönkkö TKE, Eickhoff MK, Curovic VR, Siwy J, Eder S, Denicolò S, Mayer G, Mischak H, Rossing P, Persson F.
Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
Kidney Int Rep. 2023, 29;9(2):334-346.
402.
Catanese L, Siwy J, Wendt R, Amann K, Beige J, Hendry B, Mischak H, Mullen W, Paterson I, Schiffer M, Wolf M, Rupprecht H.
Differentiating primary and secondary FSGS using non-invasive urine biomarkers
Clin Kidney J. 2023, 17(2):sfad296.
401.
Martens DS, An DW, Yu YL, Chori BS, Wang C, Silva AI, Wei FF, Liu C, Stolarz-Skrzypek K, Rajzer M, Latosinska A, Mischak H, Staessen JA, Nawrot TS; (The FLEMENGHO Investigators).
Association of Air Pollution with a Urinary Biomarker of Biological Aging and Effect Modification by Vitamin K in the FLEMENGHO Prospective Population Study
Environ Health Perspect. 2023, 131(12):127011. Epub 2023 Dec 11.
400.
Peters B, Beige J, Siwy J, Rudnicki M, Wendt R, Ortiz A, Sanz AB, Mischak H, Reich HN, Nasic S, Mahmood D, Persson A, Fernström A, Weiner M, Stegmayr B; PersTIgAN Working Group.
Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy
Nephrol Dial Transplant. 2023, 38(12):2826-2834.
399.
De Beer D, Mels CM, Schutte AE, Delles C, Mary S, Mullen W, Mischak H, Kruger R.
Urinary Peptidomics and Pulse Wave Velocity: The African-PREDICT Study
J Proteome Res. 2023, 22(10):3282-3289. Epub 2023 Sep 9.
398.
Boutin L, Latosinska A, Mischak H, Deniau B, Asakage A, Legrand M, Gayat E, Mebazaa A, Chadjichristos CE, Depret F.
Subclinical and clinical acute kidney injury share similar urinary peptide signatures and prognosis
Intensive Care Med. 2023, 49(10):1191-1202. Epub 2023 Sep 5.
397.
Mischak H.
Further comments on 'A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension'
J Hypertens. 2023, 41(10):1667.
396.
Mischak H.
Comment on 'A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension' by Lin et al.
J Hypertens. 2023, 41(10):1666.
395.
Keller F, Beige J, Siwy J, Mebazaa A, An D, Mischak H, Schanstra JP, Mokou M, Perco P, Staessen JA, Vlahou A, Latosinska A.
Urinary peptides provide information about the risk of mortality across a spectrum of diseases and scenarios
J Transl Med. 2023, 21(1):663.
394.
Jaimes Campos MA, Andújar I, Keller F, Mayer G, Rossing P, Staessen JA, Delles C, Beige J, Glorieux G, Clark AL, Mullen W, Schanstra JP, Vlahou A, Rossing K, Peter K, Ortiz A, Campbell A, Persson F, Latosinska A, Mischak H, Siwy J, Jankowski J.
Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study
Pharmaceuticals (Basel). 2023, 16(9):1298.
393.
Lohia S, Siwy J, Mavrogeorgis E, Eder S, Thöni S, Mayer G, Mischak H, Vlahou A, Jankowski V.
Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment
Int J Mol Sci. 2023, 24(17):13540.
392.
Hobson S, Mavrogeorgis E, He T, Siwy J, Ebert T, Kublickiene K, Stenvinkel P, Mischak H.
Urine Peptidome Analysis Identifies Common and Stage-Specific Markers in Early Versus Advanced CKD
Proteomes. 2023, 11(3):25.
391.
Latosinska A, Frantzi M, Siwy J.
Peptides as "better biomarkers"? Value, challenges, and potential solutions to facilitate implementation​
Mass Spectrom Rev. 2023 Jun 26. Online ahead of print.
390.
Marx D, Anglicheau D, Caillard S, Moulin B, Kochman A, Mischak H, Latosinska A, Bienaimé F, Prié D, Marquet P, Perrin P, Gwinner W, Metzger J.
Urinary collagen peptides: Source of markers for bone metabolic processes in kidney transplant recipients
Proteomics Clin Appl. 2023, 17(4):e2200118. Epub 2023 Jun 27.
389.
Peters B, Beige J, Siwy J, Rudnicki M, Wendt R, Ortiz A, Sanz AB, Mischak H, Reich HN, Nasic S, Mahmood D, Persson A, Fernström A, Weiner M, Stegmayr B; PersTIgAN working group.
Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy
Nephrol Dial Transplant. 2023, 38(12):2826-2834.
388.
Chori BS, An DW, Martens DS, Yu YL, Gilis-Malinowska N, Abubakar SM, Ibrahim EA, Ajanya O, Abiodun OO, Anya T, Tobechukwu I, Isiguzo G, Cheng HM, Chen CH, Liao CT, Mokwatsi G, Stolarz-Skrzypek K, Wojciechowska W, Narkiewicz K, Rajzer M, Brguljan-Hitij J, Nawrot TS, Asayama K, Reyskens P, Mischak H, Odili AN, Staessen JA; UPRIGHT-HTM Investigators.
Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial-First progress report
J Clin Hypertens (Greenwich). 2023, 25(6):521-533. Epub 2023 May 6.
387.
De Beer D, Mels CMC, Schutte AE, Delles C, Mary S, Mullen W, Latosinska A, Mischak H, Kruger R.
Identifying a urinary peptidomics profile for hypertension in young adults: The African-PREDICT study: Urinary peptidomics and hypertension: Urinary peptidomics and hypertension
Proteomics. 2023, 23(11):e2200444. Epub 2023 Apr 3.
386.
Devos H, Zoidakis J, Roubelakis MG, Latosinska A, Vlahou A.
Reviewing the Regulators of COL1A1
Int J Mol Sci. 2023, 24(12):10004.
385.
Catanese L, Siwy J, Mischak H, Wendt R, Beige J, Rupprecht H.
Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review
Int J Mol Sci. 2023, 24(11):9156.
384.
Davison BA, Edwards C, Cotter G, Kimmoun A, Gayat É, Latosinska A, Mischak H, Takagi K, Deniau B, Picod A, Mebazaa A.
Plasma and Urinary Biomarkers Improve Prediction of Mortality through 1 Year in Intensive Care Patients: An Analysis from FROG-ICU
J Clin Med. 2023, 12(9):3311.
383.
An DW, Yu YL, Martens DS, Latosinska A, Zhang ZY, Mischak H, Nawrot TS, Staessen JA.
Statistical approaches applicable in managing OMICS data: Urinary proteomics as exemplary case
Mass Spectrom Rev. 2023 May 4. Online ahead of print.
382.
Degenaar A, Jacobs A, Kruger R, Delles C, Mischak H, Mels C.
Cardiovascular risk and kidney function profiling using conventional and novel biomarkers in young adults: the African-PREDICT study
BMC Nephrol. 2023, 24(1):96.
381.
Rotbain Curovic V, Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Hansen TW, Havrdova T, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P; on the behalf of the PRIORITY Study Group.
Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial
J Diabetes Complications. 2023, 37(4):108433. Epub 2023 Feb 18.
380.
Lohia S, Latosinska A, Zoidakis J, Makridakis M, Mischak H, Glorieux G, Vlahou A, Jankowski V.
Glycosylation Analysis of Urinary Peptidome Highlights IGF2 Glycopeptides in Association with CKD
Int J Mol Sci. 2023, 24(6):5402.
379.
Mokou M, Mischak H, Frantzi M.
Statistical determination of cancer biomarkers: moving forward clinically
Expert Rev Mol Diagn. 2023, 23(3):187-189. Epub 2023 Mar 6.
378.
Frantzi M, Culig Z, Heidegger I, Mokou M, Latosinska A, Roesch MC, Merseburger AS, Makridakis M, Vlahou A, Blanca-Pedregosa A, Carrasco-Valiente J, Mischak H, Gomez-Gomez E.
Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination
Cancers (Basel). 2023, 15(4):1166.
377.
de Beer D, Mels CMC, Schutte AE, Delles C, Mary S, Mullen W, Mischak H, Kruger R.
A urinary peptidomics approach for early stages of cardiovascular disease risk: The African-PREDICT study
Hypertens Res. 2023, 46(2):485-494. Epub 2022 Nov 17.
376.
Mokou M, Narayanasamy S, Stroggilos R, Balaur IA, Vlahou A, Mischak H, Frantzi M.
A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures
Methods Mol Biol. 2023, 2684:59-99.